Skip to main content
Erschienen in: Wiener klinische Wochenschrift 7-8/2012

01.04.2012 | original article

Assessment of metabolic syndrome in patients with primary biliary cirrhosis

verfasst von: Tamara Alempijevic, Aleksandra Sokic-Milutinovic, Aleksandra Pavlovic Markovic, Rada Jesic-Vukicevic, Biljana Milicic, Djuro Macut, Dragan Popovic, Dragan Tomic

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 7-8/2012

Einloggen, um Zugang zu erhalten

Summary

Background

Primary biliary cirrhosis (PBC) is a chronic, progressive liver disease with elevated serum lipids. It remains unclear if hyperlipidemia increases the risk for atherosclerosis in PBC patients. Metabolic syndrome (MS) promotes the development of atherosclerotic cardiovascular disease due to abdominal obesity and insulin resistance.

Aims

The aim of this study was to assess incidence and parameters of MS, as well as subcutaneous and visceral fat using noninvasive ultrasonographic measurement in patients with PBC in our population.

Methods

We included 55 patients with PBC and 44 age- and sex-matched healthy controls (CG-control group). Anthropometric measurements (weight, height, and waist circumference), age, sex, and body mass index were recorded for patients and controls. Laboratory tests for assessing MS and liver function tests were analyzed. We used ultrasonography to determine subcutaneous and visceral fat diameter and area (SF, VF and SA, VA, respectively), as well as perirenal fat diameter (PF).

Results

Patients with PBC had significantly higher levels of cholesterol and liver function tests. There were no statistically significant difference in serum insulin and HOMA levels, as well as incidence of MS was diagnosed in 30.9 % (17/55) PBC patients and 43.2 % (19/44) controls. We registered lower amount of VF (PBC:10.92 ± 3.63 mm, CG:16.84 ± 5.51 mm,p < 0.001), VA (PBC:403.64 ± 166.97 mm2, CG:720.57 ± 272.50 mm2,p < 0.001), and PF (PBC:7.03 ± 1.82 mm, CG 10.49 ± 2.70 mm,p < 0.001) in patients with PBC.

Conclusion

MS is not more frequent in patients with PBC compared with healthy volunteers in our population. Lower amount of VF could be related to lower risk for cardiovascular events in PBC patients.
Literatur
1.
2.
Zurück zum Zitat Van Dam GM, Gips CH. Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures. Scand J Gastroenterol. 1997;32:77–83.PubMedCrossRef Van Dam GM, Gips CH. Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures. Scand J Gastroenterol. 1997;32:77–83.PubMedCrossRef
3.
Zurück zum Zitat Crippin JS, Lindor KD, Jorgensen R, et al. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology. 1992;15:858–62.PubMedCrossRef Crippin JS, Lindor KD, Jorgensen R, et al. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology. 1992;15:858–62.PubMedCrossRef
4.
Zurück zum Zitat Cash WJ, McCance DR, Young IS, et al. Primary biliary cirrhosis is associated with oxidative stress and endothelial dysfunction but not increased cardiovascular risk. Hepatol Res. 2010;40(11):1098–106.PubMedCrossRef Cash WJ, McCance DR, Young IS, et al. Primary biliary cirrhosis is associated with oxidative stress and endothelial dysfunction but not increased cardiovascular risk. Hepatol Res. 2010;40(11):1098–106.PubMedCrossRef
5.
Zurück zum Zitat Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis. 2007;194:293–9.PubMedCrossRef Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis. 2007;194:293–9.PubMedCrossRef
6.
Zurück zum Zitat Allocca M, Crosignani A, Gritti A, et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut. 2006;55:1795–800.PubMedCrossRef Allocca M, Crosignani A, Gritti A, et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut. 2006;55:1795–800.PubMedCrossRef
7.
Zurück zum Zitat Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51:265–9.PubMedCrossRef Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51:265–9.PubMedCrossRef
8.
Zurück zum Zitat Stojakovic T, Putz-Bankuti C, Fauler G, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology. 2007;46(3):776–84.PubMedCrossRef Stojakovic T, Putz-Bankuti C, Fauler G, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology. 2007;46(3):776–84.PubMedCrossRef
9.
Zurück zum Zitat Stojakovic T, Claudel T, Putz-Bankuti C, et al. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis. 2010;209(1):178–83.PubMedCrossRef Stojakovic T, Claudel T, Putz-Bankuti C, et al. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis. 2010;209(1):178–83.PubMedCrossRef
10.
Zurück zum Zitat Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an AmericanHeart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–52.PubMedCrossRef Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an AmericanHeart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–52.PubMedCrossRef
11.
Zurück zum Zitat Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469–80.PubMedCrossRef Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469–80.PubMedCrossRef
12.
Zurück zum Zitat Wang J. Waist circumference: a simple, inexpensive, and reliable tool that should be included as part of physical examinations in the doctor’s office. Am J Clin Nutr. 2003;78:902–3.PubMed Wang J. Waist circumference: a simple, inexpensive, and reliable tool that should be included as part of physical examinations in the doctor’s office. Am J Clin Nutr. 2003;78:902–3.PubMed
13.
Zurück zum Zitat Merino-Ibarra E, Artieda M, Cenarro A, et al. Ultrasonography for the evaluation of visceral fat and the metabolic syndrome. Metab Clin Exp. 2005;54:1230–5.PubMedCrossRef Merino-Ibarra E, Artieda M, Cenarro A, et al. Ultrasonography for the evaluation of visceral fat and the metabolic syndrome. Metab Clin Exp. 2005;54:1230–5.PubMedCrossRef
14.
Zurück zum Zitat Hirooka M, Kumagi T, Kurose K, et al. A technique for the measurement of visceral fat by ultrasonography: comparison of measurements by ultrasonography and computed tomography. Intern Med. 2005;44(8):794–9.PubMedCrossRef Hirooka M, Kumagi T, Kurose K, et al. A technique for the measurement of visceral fat by ultrasonography: comparison of measurements by ultrasonography and computed tomography. Intern Med. 2005;44(8):794–9.PubMedCrossRef
15.
Zurück zum Zitat Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMedCrossRef
16.
Zurück zum Zitat Solaymani-Dodaran M, Aithal GP, Card T, West J. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study. Am J Gastroenterol. 2008;103(11):2784–8.PubMedCrossRef Solaymani-Dodaran M, Aithal GP, Card T, West J. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study. Am J Gastroenterol. 2008;103(11):2784–8.PubMedCrossRef
17.
Zurück zum Zitat Floreani A, Variola A, Niro G, et al. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am J Gastroenterol. 2008;103(8):1959–65.PubMedCrossRef Floreani A, Variola A, Niro G, et al. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am J Gastroenterol. 2008;103(8):1959–65.PubMedCrossRef
18.
Zurück zum Zitat Despres JP, Cartier A, Côté M, Arsenault BJ. The concept of cardiometabolic risk: bridging the fields of diabetology and cardiology. Ann Med. 2008;40:514–23.PubMedCrossRef Despres JP, Cartier A, Côté M, Arsenault BJ. The concept of cardiometabolic risk: bridging the fields of diabetology and cardiology. Ann Med. 2008;40:514–23.PubMedCrossRef
19.
Zurück zum Zitat Allende-Vigo MZ. Pathophysiologic mechanisms linking adipose tissue and cardiometabolic risk. Endocr Pract. 2010;16:692–8.PubMedCrossRef Allende-Vigo MZ. Pathophysiologic mechanisms linking adipose tissue and cardiometabolic risk. Endocr Pract. 2010;16:692–8.PubMedCrossRef
20.
Zurück zum Zitat Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocriol Metab. 2000;10:327–32.CrossRef Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocriol Metab. 2000;10:327–32.CrossRef
21.
Zurück zum Zitat Gnacińska M, Małgorzewicz S, Guzek M, Lysiak-Szydłowska W, Sworczak K. Adipose tissue activity in relation to overweight or obesity. Endokrynol Pol. 2010;61:160–8.PubMed Gnacińska M, Małgorzewicz S, Guzek M, Lysiak-Szydłowska W, Sworczak K. Adipose tissue activity in relation to overweight or obesity. Endokrynol Pol. 2010;61:160–8.PubMed
22.
Zurück zum Zitat Duvnjak L, Duvnjak M. The metabolic syndrome—an ongoing story. J Physiol Pharmacol. 2009;60(7):19–24.PubMed Duvnjak L, Duvnjak M. The metabolic syndrome—an ongoing story. J Physiol Pharmacol. 2009;60(7):19–24.PubMed
23.
24.
Zurück zum Zitat Balmer ML, Joneli J, Schoepfer A, Stickel F, Thormann W, Dufour JF. Significance of serum adiponectin levels in patients with chronic liver disease. Clin Sci (Lond). 2010;119:431–6.CrossRef Balmer ML, Joneli J, Schoepfer A, Stickel F, Thormann W, Dufour JF. Significance of serum adiponectin levels in patients with chronic liver disease. Clin Sci (Lond). 2010;119:431–6.CrossRef
25.
Zurück zum Zitat Tacke F, Wüstefeld T, Horn R, et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol. 2005;42:666–73.PubMedCrossRef Tacke F, Wüstefeld T, Horn R, et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol. 2005;42:666–73.PubMedCrossRef
26.
Zurück zum Zitat Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91–100.PubMed Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91–100.PubMed
27.
Zurück zum Zitat Aygun C, Senturk O, Hulagu S, et al. Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2006;18:175–80.PubMedCrossRef Aygun C, Senturk O, Hulagu S, et al. Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2006;18:175–80.PubMedCrossRef
Metadaten
Titel
Assessment of metabolic syndrome in patients with primary biliary cirrhosis
verfasst von
Tamara Alempijevic
Aleksandra Sokic-Milutinovic
Aleksandra Pavlovic Markovic
Rada Jesic-Vukicevic
Biljana Milicic
Djuro Macut
Dragan Popovic
Dragan Tomic
Publikationsdatum
01.04.2012
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 7-8/2012
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-012-0162-9

Weitere Artikel der Ausgabe 7-8/2012

Wiener klinische Wochenschrift 7-8/2012 Zur Ausgabe